JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on March 14, 2016 at 16:00 (EET). To join the webinar please follow the instructions below.

Webinar is  hosted by the Member of the Management Board Salvis Lapiņš. The presentation is held in English.

Salvis Lapiņš informs about JSC Olainfarm latest activities and analyzes the financial results of the fourth quarter 2015 and non-audited financial results of 12 months 2015.

After the presentation investors are welcome to ask questions.

During the webinar the enclosed presentation is being presented: Webinar Presentation: 4th quarter and the whole 2015

What is webinar?
Webinar is a virtual conference, during which company’s representative gives information about the company, its activities and future plans. Webinar allows interactive communication and provides an opportunity to ask questions and get answers directly from the company.

How to join the webinar?
All you need is a computer with internet connection and headphones.

To join the webinar, we invite you to register via ej.uz/OLF_YE2015.

You will be provided with the webinar link and instructions to join webinar successfully. When joining the webinar for the first time, you will be asked to download the system application on your computer which will take only few seconds.

For more information on webinar service please visit: http://www.nasdaqbaltic.com/en/products-services/webinars-3/
Join the webinar and be the first one to hear the news!

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on March 14, 2016 at 16:00 (EET). To join the webinar please follow the instructions below.

Webinar will be hosted by the Member of the Management Board Salvis Lapiņš. The presentation will be held in English.

During the webinar Salvis Lapiņš will inform about JSC Olainfarm latest activities and analyze the financial results of the fourth quarter 2015 and non-audited financial results of 12 months 2015.

After the presentation investors are welcome to ask questions. Due to the limited webinar time, please send in your questions in advance till March 13 to e-mail: ieva.unda@nasdaq.com or Investors’ portal naudaslietas.lv.

What is webinar?
Webinar is a virtual conference, during which company’s representative gives information about the company, its activities and future plans. Webinar allows interactive communication and provides an opportunity to ask questions and get answers directly from the company.

How to join the webinar?
All you need is a computer with internet connection and headphones.

To join the webinar, we invite you to register via ej.uz/OLF_YE2015.

You will be provided with the webinar link and instructions to join webinar successfully. When joining the webinar for the first time, you will be asked to download the system application on your computer which will take only few seconds.

For more information on webinar service please visit: http://www.nasdaqbaltic.com/en/products-services/webinars-3/
Join the webinar and be the first one to hear the news!

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

Consolidated financial report of JSC Olainfarm for 2015 shows that the Group has set yet another profit record, as it made a net profit of 14.8 million euros in 2015. This represents an increase by 21% compared to 2014 and by 7% compared to 2012, when the previous profit record of 13.88 million euros was set.

Sales of JSC Olainfarm have increased by 4% compared to 2014 and was at 97.6 million euros. Thus, this has also been the best year in corporate history in terms of sales as well.

4th  quarter of 2015 has in terms of sales been the best last quarter in corporate history, as sales of the Group reached 25.7 million euros, which exceeds the sales made during 4th quarter of 2014 by 8%.  This has been achieved despite the fact that sales to many important markets, including, Ukraine, Belarus, UK and Poland were shrinking.

“Last year has really been a stamina test for Olainfarm in CIS markets. Local currencies remained considerably turbulent in Russia, Belarus, Ukraine and Kazakhstan. Belarus continues tightening imports of several products, including pharmaceuticals.  Therefore we not only try to strengthen our marketing efforts in these countries to preserve our positions, but also work towards differentiation of our sales markets. This year we plan to make a lot of efforts to launch our Turkish sales and continue with what we have started in several other new markets,” says Valerijs Maligins, Chairman of the Board of JSC Olainfarm.

During 2015 the most rapid sales growth has been achieved to the Netherlands, where sales grew by 107%.  This is where products for World Health Organization’s anti-tuberculosis program are shipped.  In 2015 sales to Tajikistan increased by 39%, sales to Latvia increased by 11%, sales to Kazakhstan increased by 7% and sales to Uzbekistan increases by 3%.  Sales to all other countries increased by 23 on average. Sales to Belarus shrunk by 19%, sales to Poland shrunk by 13%, sales to Ukraine decreased by 7%, sales to UK shrunk by 6% and sales to Russia decreased by 1%.  Major sales markets of JSC Olainfarm in 2015 were Russia, Latvia, Ukraine, Belarus and The Netherlands.

During the reporting registration processes have been launched in Bosnia And Herzegovina; Vietnam, Myanmar; GMP audit by Turkish pharmaceutical authorities has been passed, and bioavailability tests for Turkish registration completed, allowing the company to proceed with registration in Turkey. New forms have been developed for Gripoflex 325 (with reduced content of paracetamol), ACC 200mg powder, and lactose free Memantine tablets of 10mg and 20mg. The work continues at development of new combined prolonged activity form of nitrofurantoin. Two new food supplements have been developed and registered in Baltic countries with urological and hepatological application. Food supplement Jogurt Babydrops has been registered in the Baltics and is planned for further registration in 14 countries.

During the 4th quarter alone 4 registration processes have been completed in Tajikistan, Turkmenistan and Moldova, files are being prepared for South Africa, Croatia and Iraq.

Annual meeting of shareholders of JSC Olainfarm held on June 11, 2015 approved operating plan of the Group for 2015.  According to it, sales of the Group in 2015 are planned to be 100 million euros, but the net profit will reach 15 million euros.  According to this unaudited report for 2015, during this period 96% of annual sales target and 99% of annual profit target is met.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

Preliminary consolidated results of JSC Olainfarm for December 2015 show that sales of the company have reached 7.4 million euros, which represents a reduction by 5% compared to the same period one year ago. The biggest sales increase was achieved in Albania, where sales grew by 153%. Sales to The Netherlands grew by 145%, sales to Georgia by 138% and sales to Tajikistan by 89%. Significant shipments during this period have also been made to Uzbekistan. Major sales markets of JSC Olainfarm during December 2015 were Russia, Latvia, and The Netherlands.

Sales of pharmacy chain of Latvijas aptieka Ltd. in December 2015 were 1.62 million euros, which represents an increase by 42% compared to the same period one year ago.  62 pharmacies were operating during December. Sales of Silvanols Ltd. during December were 0.52 million euros, which represents an increase by 24% compared to December 2014. During this period products of Silvanols Ltd. were sold to four European countries and with assistance from Olainfarm, also to Belarus and Azerbaijan.

In twelve months of 2015, according to preliminary figures, the consolidated sales of JSC Olainfarm reached 98.09 million euros, which represents an increase by 5% compared to the same period of 2014. The most rapid sales increase in 2015 was achieved in The Netherlands, where sales grew by 107%. Major sales markets of JSC Olainfarm during 2015 were Russia, Latvia, Ukraine, Belarus and The Netherlands.

During 12 months of 2015, sales of pharmacy chain of Latvijas aptieka Ltd. were 16.9 million euros, which represents and increase by 13% compared to 12 months of 2014. Sales of Silvanols Ltd. during 2015 was 4.4 million euros, which represents an increase by 26% compared to 2014, when Silvanols Ltd. made sales worth 3.5 million euros. Products of Silvanols Ltd. during 2015 were sold to 13 countries on two continents, and with the help of JSC Olainfarm also to Belarus, Kazakhstan and Azerbaijan.

According to unconsolidated preliminary results, sales of JSC Olainfarm during December 2015 were 6.08 million euros, which represents a reduction by 12% compared to December 2014. The biggest sales increase was achieved in Albania, where sales grew by 153%. Sales to The Netherlands grew by 145%, sales to Georgia grew by 138%, while sales to Tajikistan grew by 89%. Significant shipments during this period were also made to Uzbekistan. The major sale markets of JSC Olainfarm in December 2015 were Russia, Latvia, and The Netherlands. In total during this period JSC Olainfarm sold its products in 24 countries on three continents.

According to preliminary unconsolidated results, during 12 months of 2015, sales of JSC Olainfarm were 85.67 million euros, which represents an increase by 5% compared to the same period of 2014. The most rapid sales increase in 2015 was achieved in The Netherlands, where sales grew by 107%. Sales to Turkmenistan grew by 46%, sales to Tajikistan grew by 39% and sales to Latvia grew by 25%. According to preliminary unconsolidated results, the major sales markets of JSC Olainfarm in 2015 were Russia, Ukraine, Latvia, Belarus and The Netherlands. In total during 2015 JSC Olainfarm sold its products in 42 countries on five continents.

Annual General Meeting of shareholders of JSC Olainfarm, held on June 11, 2015 approved operating plan of the company, according to which the unconsolidated sales of the company in 2015 will reach 87 million euros, while consolidated sales will reach 100 million euro. According to these preliminary sales figures, the company has attained 98% of annual target for unconsolidated sales and 98% of annual target for consolidated sales.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

Salvis Lapins
JSC Olainfarm
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv

Unaudited profit and loss account of JSC Olainfarm for nine months of 2015 shows that with the sales worth 71.9 million euros, the Group has experiences the best nine months in its corporate history. Sales have increased by 3%, while profit has remained almost unchanged, as it has shrunk by 1000 euros and equals 12.105 million euros. Main sales markets of JSC Olainfarm during this period were Russia, Latvia, Ukraine, Belarus and The Netherlands.

3rd quarter of 2015 has in terms of sales been the best third quarter in corporate history, as sales of the Group reached 21.8 million euros, which exceeds the sales made during 3rd quarter of 2014 by more than 2%. During this period the company made a net profit of 2.8 million euros, which represents a reduction by 12% compared to the same period of last year.

“Successful operations in Latvia and Lithuania and good cooperation with the World Health Organization’s anti-tuberculosis program are the key driving forces behind these record sales. However, we realize that continuing with such series of records becomes increasingly difficult as new challenges are appearing in several important CIS markets. In addition to economic instability and depreciating local currencies have left a significant impact on purchasing power of local population. In addition to these factors, governments of CIS countries use administrative methods to limit imports of different products, including pharmaceuticals. Therefore we have to continue searching for possibilities to further diversify our sales markets and strengthen our presence there”, says Salvis Lapins, Member of company’s Board.

During nine months of 2015 Company’s sales grew in Latvia (by 9%), The Netherlands (WHO shipments, by 181%), Kazakhstan (by 2%), Lithuania (by 185), and other countries (by 28% on average). Sales have been shrinking to Ukraine (by 15%), Belarus (by 7%), UK (by 9%), Uzbekistan (by 6%) and Russia (by 3%). In total, during this nine months period JSC Olainfarm was selling its products to 41 countries on five continents.

During the 3rd quarter, 5 registration processes have been completed in Azerbaijan, Ukraine and Romania. A food supplement Jogurt Babydrops has been registered in Latvia. Further extension of Gripoflex line has been launched.

Annual meeting of shareholders of JSC Olainfarm held on June 11, 2015 approved operating plan of the Group for 2015. According to it, sales of the Group in 2015 are planned to be 100 million euros, but the net profit will reach 15 million euros. According to this unaudited report for 9 months of 2015, during this period 72% of annual sales target and 81% of annual profit target is met.

JSC Olainfarm UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE 9 MONTHS PERIOD ENDED 30 SEPTEMBER 2015

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 40 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

Salvis Lapins
Member of the Management Board
Rupnicu iela 5, Olaine, Latvia, LV 2114
Phone: +371 6 7013 717
Fax: +371 6 7013 777
E-mail: Salvis.Lapins@olainfarm.lv